The Claim
In adolescents with obesity and type 2 diabetes, 36 weeks of weekly administration of Mazdutide 6 mg combined with metformin and insulin was associated with complete resolution of hepatic steatosis on ultrasound, with observation beginning at week 14 and sustained through week 36.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adolescents with obesity and type 2 diabetes, treatment with weekly Mazdutide 6 mg along with metformin and insulin for 36 weeks was linked to the complete disappearance of liver fat detected by ultrasound, starting at week 14 and continuing through week 36.
See the scientific wording
In an adolescent with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin was associated with complete resolution of hepatic steatosis on ultrasound, observed at week 14 and sustained through week 36.
The drug activates two receptors in the liver and pancreas, which makes the liver burn more fat for energy and stops excess fat from entering from fat tissue. This clears the fat buildup in the liver, and the improvement lasts as long as the treatment continues.
What the research says
1 studyA teen with obesity and diabetes got a weekly shot called Mazdutide along with his other medicines, and his fatty liver went away by week 14 and stayed gone until the end of treatment — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.